922TiPEV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). (23rd October 2018) - Petrylak, D P; Rosenberg, J; Duran, I; Loriot, Y; Sonpavde, G; Wu, C; Gartner, E; Melhem-Bertrandt, A; Powles, T